CARDIOMETABOLIC RISK FACTORS IN THE INSANE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper deals with a cardiovascular risk in patients with mental illnesses. Carbohydrate and lipid metabolic disturbances that may be aggravated by antipsychotic therapy are inherent in patients with schizophrenia and recurrent affective disorders. Therapy with current neuroleptics is frequently accompanied by the development of obesity and metabolic syndrome. The risk for these abnormalities depends on a used drug and possibly genetic causes. The issues in the screening and monitoring of metabolic abnormalities are discussed in patients who long receive antipsychotics.

Full Text

Restricted Access

About the authors

A. Panferov

Email: a_panferov@mail.ru

T. Avdeyeva

References

  1. Данилов Д.С. Классификация антипсихотических средств и их значение для выбора терапии шизофрении (к 60-летию появления нейролептиков) // Журн. неврол. и психиат. им. С.С. Корсакова. - 2011; 10: 91-100.
  2. Allison B.D., Mentore J.L., Heo M. et al. Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis // Am. J. Psychiat. - 1999; 156 (11): 1686-96.
  3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes // Diabetes Care. - 2004; 27: 596-601.
  4. Bernstein H.G., Bogerts B., Lendeckel U. Cathepsin K and metabolic abnormalities in schizophrenia // Arterioscler. Thromb. Vasc. Biol. - 2008; 28 (12): 163.
  5. Bradford D.W., Kimm M.M., Braxton L.E. et al. Access to Medical Care Among Persons With Psychotic and Major Affective Disorders // Psychiat. Serv. -2008; 59 (8): 847-52.
  6. Brown L.C., Majumdar S.R., Newman S.C. et al. History of depression increases risk of type 2 diabetes in younger adults // Diabetes Care. - 2005; 28: 1063-7.
  7. Bushe C.J., Leonard B.E. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials // J. Clin. Psychiatry. - 2007; 68 (11): 1682-90.
  8. Canadian Diabetes Association. Position paper: antipsychotic medications and associated risks of weight gain and diabetes // Canad. J. Diabetes. - 2005; 29: 111-2.
  9. Carney C.P., Jones L., Woolson R.F. Medical Comorbidity in Women and Men with Schizophrenia. A Population-Based Controlled Study // J. Gen. Intern. Med. - 2006; 21: 1133-7.
  10. Correll C.U., Druss B.G. et al. Findings of a U.S. national cardiometabolic screening program among 10 084 psychiatric outpatients // Psychiat. Serv. - 2010; 61 (9): 892-8.
  11. De Hert M., van Winkel R., Van Eyck D. et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a crosssectional study // Clin. Pract. Epidemiol. Ment. Health. - 2006; 2: 14.
  12. De Nayer A., De Hert M., Scheen A. et al. Belgian consensus on metabolic problems associated with atypical antipsychotics // Int. J. Psychiat. Clin. Practice. -2005; 9: 130-7.
  13. Ellingrod V.L., Miller D.D., Taylor S.F. et al. Metabolic Syndrome and Insulin Resistance in Schizophrenia Patients Receiving Antipsychotics Genotyped for the Methylenetetrahydrofolate Reductase (MTHFR) 677C/T and 1298A/C Variants // Schizophr. Res. - 2008; 98 (1-3): 47-54.
  14. Engl J., Laimer M., Niederwanger A. et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells // Molecular. Psychiatry. - 2005; 10: 1089-96.
  15. Expert Group «Schizophrenia and Diabetes 2003» Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary // Br. J. Psychiatry. Suppl. - 2004; 47: 112-4.
  16. Fiedorowicz J.G., Palagummi N.M., Forman-Hoffman V.L. et al. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder // Ann. Clin. Psychiatry. - 2008; 20 (3): 131-7.
  17. Goldberg R.W., Kreyenbuhl J.A., Medoff D.R. et al. Quality of diabetes care among adults with serious mental illness // Psychiatr. Serv. - 2007; 58 (4): 536-43.
  18. Holt R.I.G., Peveler R.C. Antipsychotic drugs and diabetes an application of the Austin Bradford Hill criteria // Diabetologia. - 2006; 49: 1467-76.
  19. Ko F., Tallerico T., Seeman P. Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine // Synapse. -2006; 60 (2): 141-51.
  20. Kohen D. Diabetes mellitus and schizophrenia: historical perspective // Br. J. Psychiatry. - 2004; 184 (47): 64-6.
  21. Lambert T.J., Chapman L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement // Med. J. Aust. - 2004; 181: 544-8.
  22. Leucht S., Carves C., Arbter D. et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis // Lancet. -2009; 373 (9657): 31-41.
  23. Levine J., Stahl Z., Sela B.A. et al. Elevated homocysteine levels in young male patients with schizophrenia // Am. J. Psychiat. - 2002; 159 (10): 1790-2.
  24. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia // N. Engl. J. Med. - 2005; 353 (12): 1209-23.
  25. Mackin P., Bishop D.R., Watkinson H.M.O. A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients // BMC Psychiat. - 2007, 7: 28.
  26. Marder S.R., Essock S.M., Miller A.L. et al. Physical Health Monitoring of Patients With Schizophrenia // Am. J. Psychiatry. - 2004; 161: 1334-49.
  27. Melkersson K. Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro // Eur. Neuropsychopharmacol. -2004; 14: 115-9.
  28. Melkersson K., Jansson E. The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro // Neuroendocrinol. Lett. - 2005; 26 (3): 205-8.
  29. Mezuk B., Eaton W.W., Albrecht S. et al. Depression and type 2 diabetes over the lifespan: a meta-analysis // Diabetes Care. - 2008; 31 (12): 2383-9.
  30. Nasrallah H.A., Meyer J.M., Goff D.C. et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline // Schizophr. Res. - 2006; 86: 15-22.
  31. Oriot P., Feys J.-L., Mertens de Wilmars S. et al. Insulin sensitivity, adjusted ß-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: A nine-month prospective study // Diab. Met. - 2008; 34: 490-6.
  32. Osborn D.P., Levy G., Nazareth I. et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database // Arch. Gen. Psychiatry. - 2007; 64 (2): 242-9.
  33. Osborn D.P., Wright C.A., Levy G., King M.B. et al. Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: systematic review and meta-analysis // BMC Psychiat. - 2008; 8: 84.
  34. Ösby U., Correia N., Brandt L. et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study // BMJ. - 2000; 321: 483-4.
  35. Parker С., Coupland C., Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study // BMJ. - 2010; 341: 4245-54.
  36. Ray W.A., Chung C.P., Murray K.T. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death // N. Engl. J. Med. - 2009; 360 (3): 225-35.
  37. Renrong Wu, Jingping Zhao, Ping Shao et al. Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study // J. Cent. South. Univ. (Med. Sci.). - 2011; 36 (8): 720-3.
  38. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia // Am. J. Psychiat. - 2003; 160 (2): 284-9.
  39. Ryan M.C.M., Flanagan S., Kinsella U. et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia // Life Sci. - 2004; 74 (16): 1999-2008.
  40. Saha S., Chant D., McGrath J. A Systematic Review of Mortality in Schizophrenia. Is the Differential Mortality Gap Worsening Over Time? // Arch. Gen. Psychiat. - 2007; 64 (10): 1123-31.
  41. Scheen A.J., De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics // Diab. Met. - 2007; 33: 169-75.
  42. Smith M., Hopkins D., Peveler R. et al. First versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and metaanalysis // Br. J. Psychiat. - 2008; 192 (6): 406-11.
  43. Sowell M., Mukhopadhyay N., Cavazzoni P. et al. Evaluation of Insulin Sensitivity in Healthy Volunteers Treated with Olanzapine, Risperidone, or Placebo: A Prospective, Randomized Study Using the Two-Step Hyperinsulinemic, Euglycemic Clamp // J. Clin. Endocrinol. Metab. - 2003; 88 (12): 5875-80.
  44. Thakore J.H., Mann J.N., Vlahos I. et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia // Int. J. Obes. - 2002; 26: 137-41.
  45. Yang M., Sun J., Liu J. et al. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism // Arterioscle. Thromb. Vasc. Biol. - 2008; 28: 2202-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies